PHASE II TRIAL OF CONTINUOUS SUNITINIB IN PATIENTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA (SURGE 01-07)
Hutterer, M; Martha, N; Sabine, E; Thaddaus, G; Florian, S; Christine, M; Stefan, O; Richard, G; Martin, M; Johanna, B; Jochen, T; Ullrich, H; Wolfgang, W; Peter, V; Gunther, S NEURO-ONCOLOGY. 2011; 13: 88-88.
Transient elastography (FibroScan) for the prediction of liver toxicity following autologous or allogeneic HSCT
Nachbaur, D; Auberger, J; Graziadei, I; Vogel, W; Clausen, J ONKOLOGIE. 2011; 34: 277-277.
Bone marrow may be the preferable graft source for transplant recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors
Clausen, J; Kircher, B; Schumacher, P; Grabmer, C; Muhlbacher, A; Gastl, G; Nachbaur, D BONE MARROW TRANSPL. 2011; 46: S121-S121.
Breakthrough fungal infections (bIFI), fungal colonization and emergence of resistant strains during posaconazole (PCZ) prophylaxis in patients at risk. Real-life data from a single center institutional retrospective observational study
Auberger, J; Clausen, J; Mrazek, C; Lass-Florl, C; Nachbaur, D ONKOLOGIE. 2011; 34: 232-232.
Differentialdiagnose der Gelenksentzündungen, Kollagenosen
Psenak, O; PMU-Lehre für 3. Jahrgang:_x000D_ Pathophysiologische des muskuloskelettalen Apparates; 04.10.2011; Salzburg. 2011.
Orencia Kasuistiken
Psenak, O; ACTION-Investigatormeeting Kasuistiken; 25.11.2011; Anif. 2011.
Kollagenosen
Psenak, O; Fortbildungsseminar für Turnusärzte SALK; 11.01.2011; Salzburg. 2011.
S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer._x000D_
Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Stoeger, H; Dubsky, P; Jakesz, R; Singer, C, Eidtmann, H; Fesl, C; Eiermann, W; Marth, C; Greil, R; Cancer Research, 24 Supplement_x000D_ _x000D_ . 2011. 71: 1-2.
VEGF, PARP, mTOR, EGFR und PI3K beim HER2-negativen Mammakarzinom
Gampenrieder, SP; Mlineritsch, B; Greil, R. Universum für Innere Medizin 2011. 2011. 4: 79-80.
S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+ docetaxel (DOC) as first-line therapy for HER2− positive locally recurrent/metastatic breast cancer (LR/mBC)_x000D_
Gianni, L; Romieu, G; Lichinitser, M; Serrano, S; Mansutti, M Pivot, X; Smirnova, I; Moliterni, A; Andre, F; Chan, A; Lipatov, O; Chan, S; Wardley, A; Greil, R; Provencher, L; Moore, N; Prot, S; Semiglazov, V; Cancer Research, 24 Supplement_x000D_ . 2011. 71: 4-8.
